|
| Tuesday, 6 June 2023, 20:00 HKT/SGT | |
| |  | |
Source: GeneTex | |
|
|
|
IRVINE, CA, June 6, 2023 - (ACN Newswire) - GeneTex, a multinational antibody manufacturing company, is leveraging its recombinant monoclonal antibody production platform to produce best-in-class biomedical research reagents. The specificity of these new antibodies is established through meticulous in-house validation testing based on knockdown/knockout methodologies complemented by other strategies. GeneTex has employed this process to develop and thoroughly validate its new programmed death-ligand 1 (PD-L1) recombinant rabbit monoclonal antibody for immunohistochemistry (IHC).
The interaction between PD-L1 (CD274/B7-H1) and its receptor programmed death-1 (PD-1) is not only a focus of cancer immunotherapy research but also has major therapeutic relevance for many solid malignancies. PD-L1 is an immune checkpoint inhibitor that binds to PD-1 expressed on T cells and other effectors to quash immune system overactivation and autoimmunity. Cancer cells exploit this and overexpress PD-L1, creating an immunosuppressive state through induced cell death of anti-tumor T cells. Thus, gauging PD-L1 expression on tumor cells can identify cancers that may respond to anti-PD-L1/PD-1 agents. Given the importance of PD-L1 detection in patient tumor samples for both prognostic and treatment considerations, reliable reagents are clearly essential for both research and clinical decision-making.
Immunohistochemistry is utilized routinely in both academic and clinical settings to determine PD-L1 expression in both normal and cancerous tissues. GeneTex's recombinant rabbit monoclonal antibody (PD-L1 antibody [HL1041]) is a cited, PD-L1-specific, knockout-validated reagent that performs in three applications (i.e., western blot, immunocytochemistry, and IHC). To further evaluate this antibody's IHC capabilities, GeneTex enlisted the assistance of MS Validated Antibodies GmbH (MSVA), a company with demonstrated proficiency in IHC optimization that has assessed over 5000 antibodies for their functionality in formalin-fixed tissue IHC. MSVA completed an extensive analysis of the GeneTex antibody's staining on tumor samples and a broad array of normal tissues, comparing the signal to that of another well-established PD-L1 antibody (see Figure). GeneTex clone [HL1041] exhibited excellent sensitivity and specificity. Marco Sauter, MSVA CEO, commented, "As formalin fixation alters the structure and accessibility of many epitopes, a trustworthy antibody validation for IHC invariably requires the analysis of a very broad range of formalin-fixed tissues. Our analysis of more than 70 different normal tissue types and of a broad range of different cancers exceeds what regulatory agencies currently require. We are gratified that our MSVA approach could help to identify PD-L1 clone [HL1041] with binding properties that are comparable to the most established PD-L1 antibodies on the market."
The need for quality antibodies to visualize the expression of biomarkers crucial for cancer biology research and patient care remains vast, particularly for IHC. GeneTex is presently developing reagents against a number of key targets. Allen Lee, GeneTex's Vice President of Business Development, stressed the importance of expertise-based collaborations to create gold-standard products for scientists and clinicians: "GeneTex is excited to extend our partnership with MSVA. Their IHC validation services align perfectly with GeneTex's core mission, which is to provide the biomedical community with the highest quality immunological reagents supported by extensive research, development, and validation."
GeneTex products are for research use only. Not for diagnostic or therapeutic procedures.
Media Contact:
Allen Lee
Phone: 949.553.1900
Email: allensl@genetex.com
www.genetex.com
Contact Information
Allen Lee
Vice President - Business Development
allensl@genetex.com
(949)553-1900
Topic: Press release summary
Source: GeneTex
Sectors: BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| |
Latest Press Releases
TruMerit and Credivera Issue First Verifiable Digital Credentials for Global Healthcare Professionals
May 8, 2026 23:00 HKT/SGT
|
|
|
Sydney and Melbourne kick off ninth edition of PropertyGuru Asia Property Awards in Australia 
May 8, 2026 14:40 HKT/SGT
|
|
|
How to Travel More Often Without Increasing Your Budget
May 8, 2026 13:00 HKT/SGT
|
|
|
How to Clear the Strait of Hormuz from the Air: UMag Solutions Launches F1Mag(R) - an Unmanned Solution for Rapid Naval Mine Detection and Anti-Submarine Warfare
May 7, 2026 20:30 HKT/SGT
|
|
|
AstraZeneca and OMP Demonstrate Planning at the Speed of Change at Gartner Supply Chain Symposium/Xpo(TM) 2026
May 7, 2026 20:00 HKT/SGT
|
|
|
Focus Graphite Announces One of the Largest Identified Graphite Deposits Globally at the Lac Tetepisca Project
May 7, 2026 17:29 HKT/SGT
|
|
|
Nissin Foods Forms Joint Capital Investment with Itochu HK to Strengthen Distribution Platforms in PRC Markets
May 7, 2026 16:55 HKT/SGT
|
|
|
Fujitsu Digitalizes Management of Japan's Reserve Self-Defense Force for Ministry of Defense, Enhancing Efficiency
Thursday, May 7, 2026 1:02:00 PM
|
|
|
Neat Appoints Javed Khan as CEO to Lead AI Transformation
May 7, 2026 12:53 HKT/SGT
|
|
|
Exito Media Concepts Announces the 47th Edition of the Digital Transformation Summit Philippines
May 7, 2026 07:53 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
